TEL
AVIV, Israel, March 23,
2022 /PRNewswire/ -- Chemomab Therapeutics Ltd.
(Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company
focused on the discovery and development of innovative therapeutics
for fibrotic and inflammatory diseases with high unmet need, today
announced that management will participate in a panel discussion at
the virtual Cantor Fitzgerald Rare Orphan Disease Summit on
March 29, 2022.
Adi Mor, PhD, co-founder and
Chief Scientific Officer of Chemomab, will participate in the
panel.
Cantor Fitzgerald Rare Orphan Disease Summit
(virtual)
Panel:
Platforms and Pipelines in a Product: How One Concept Could Have
Multiple Applications Across Rare Diseases
Presenter: Dr.
Adi Mor, Chemomab co-founder and
Chief Scientific Officer
Date:
March 29, 2022
Time:
9:00 am – 10:15 am ET
Please reach out to your Cantor Fitzgerald representative to
access the Rare Orphan Disease Summit.
About Chemomab Therapeutics Ltd.
Chemomab is a
clinical-stage biotechnology company focusing on the discovery and
development of innovative therapeutics for fibrotic and
inflammatory diseases with high unmet need. Based on the unique and
pivotal role of the soluble protein CCL24 in promoting fibrosis and
inflammation, Chemomab developed CM-101, a monoclonal antibody
designed to bind and block CCL24 activity. CM-101 has demonstrated
the potential to treat multiple severe and life-threatening
fibrotic and inflammatory diseases. It is currently in two Phase 2
clinical trials—one in primary sclerosing cholangitis and the
second in liver fibrosis, with a Phase 2 trial in systemic
sclerosis expected to begin in 2022. For more information on
Chemomab, visit www.chemomab.com.
Contacts:
Investor
Relations:
|
Media:
|
Irina Koffler
|
Barbara
Lindheim
|
LifeSci Advisors,
LLC
|
Chemomab
Therapeutics
|
Phone:
+1-917-734-7387
|
Consulting Vice
President
|
ir@chemomab.com
|
Investor & Public
Relations,
|
|
Strategic
Communications
|
|
Phone:
+1-917-355-9234
|
|
barbara@chemomab.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/chemomab-therapeutics-to-participate-in-cantor-fitzgerald-rare-orphan-disease-summit-301508580.html
SOURCE Chemomab Therapeutics, Ltd.